Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. News
  7. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

H Lundbeck A/S : Lundbeck Drug Improves Symptoms in People With Major Depressive Disorder, Anxiety Disorder

05/03/2021 | 02:36am EDT


© MT Newswires 2021
All news about H. LUNDBECK A/S
07/22H LUNDBECK A/S : What do you mean brain health?
PU
07/01Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Ass..
CI
06/15#1VOICESUMMIT : Partnering with the advocacy community to further brain health a..
PU
06/11H LUNDBECK A/S : Lundbeck CEO, Deborah Dunsire, warns that we could be on the br..
PU
05/31H LUNDBECK A/S : Interpretation Of The Term "export" In The Indian Patent Contex..
AQ
05/26H LUNDBECK A/S : Transactions with shares and linked securities in H. Lundbeck A..
AQ
05/24H LUNDBECK A/S : The Hunt for a New Weapon Against Schizophrenia
PU
05/20Verantos and Lundbeck Announce Partnership for Migraine Care Implementing Adv..
CI
05/11H LUNDBECK A/S : Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is..
AQ
05/11H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021
CI
More news
Financials
Sales 2021 16 626 M 2 631 M 2 631 M
Net income 2021 1 484 M 235 M 235 M
Net Debt 2021 2 283 M 361 M 361 M
P/E ratio 2021 27,7x
Yield 2021 1,67%
Capitalization 37 802 M 5 980 M 5 983 M
EV / Sales 2021 2,41x
EV / Sales 2022 2,13x
Nbr of Employees 5 551
Free-Float 30,7%
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 190,25 DKK
Average target price 240,93 DKK
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders Götzsche Chief Financial Officer & Executive Vice President
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-6.61%6 178
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
ELI LILLY AND COMPANY41.25%209 276
NOVARTIS AG0.20%207 246